Efficacy studies of Reactive Skin Decontamination Lotion, M291 Skin Decontamination Kit, 0.5% bleach, 1% soapy water, and Skin Exposure Reduction Paste Against Chemical Warfare Agents, Part 1: Guinea pigs challenged with VX

Cutaneous and Ocular Toxicology

Volumn 30, Issue 1, 2011, Pages 15-28

  Braue Jr , Ernest H ^a   Smith, Kelly H ^a   Doxzon, Bryce F ^a   Lumpkin, Horace L ^a   Clarkson, Edward D ^a  

^a US ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL DEFENSE   (United States)

Author keywords

barrier skin creams; chemical warfare agents; Decontamination; delayed decontamination; nerve agents; personnel decontamination; skin decontamination; Skin Exposure Reduction Paste Against Chemical Warfare Agents; VX

Indexed keywords

BLEACHING AGENT; CHEMICAL WARFARE AGENT; METHYLPHOSPHONOTHIOIC ACID S (2 DIISOPROPYLAMINOETHYL) O ETHYL ESTER; SERPACWA; SOAPY WATER; UNCLASSIFIED DRUG; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; GUINEA PIG; LD 50; LOTION; M291 SKIN DECONTAMINATION KIT; NONHUMAN; SKIN DECONTAMINATION; SKIN PROTECTION; SKIN TOXICITY;

ACUTE TOXICITY TESTS; ADMINISTRATION, CUTANEOUS; ANIMALS; CHEMICAL WARFARE AGENTS; DECONTAMINATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EMOLLIENTS; GUINEA PIGS; LETHAL DOSE 50; MALE; OINTMENTS; ORGANOTHIOPHOSPHORUS COMPOUNDS; SKIN; SKIN CARE; TREATMENT OUTCOME;

ANIMALIA; CAVIA;

EID: 79951605348     PISSN: 15569527     EISSN: 15569535     Source Type: Journal    
DOI: 10.3109/15569527.2010.515280     Document Type: Article

References (36)

1. McCreery MJ. U. S. Patent 5, 607, 979, 4 March 1997.
2. Braue EH Jr, Boardman CH, Hurst, CG. Decontamination of chemical casualties. In: Tuorinsky, SD, ed. Medical Aspects of Chemical Warfare. In: Lenhart, MK, ed. Textbook of Military Medicine; Washington, DC: Department of the Army, Office of the Surgeon General, Borden Institute. 2008:527-557.
3. Sidell FR. Nerve agents. In: Sidell FR. Takafuji ET, Franz DR, eds. Medical Aspects of Chemical and Biological Warfare. In: Zajtchuk R, Bellamy RF, eds. Textbook of Military Medicine; Washington, DC: Department of the Army, Office of the Surgeon General, Borden Institute. 1997:129-179.
4. United Nations. Report of the mission dispatched by the Secretary-General to investigate allegations of the use of chemical weapons in the conflict between the Islamic Republic of Iran and Iraq. New York, NY: United Nations security Council; 12 Mar. 1986. Document 5/17911.
5. Spiers EM. Chemical and Biological Weapons: A Study in Proliferation; London, UK: St. Martin's Press. 1994:18.
6. Winkenwerder W. US demolition operations at Khamisiyah. Final report; Washington, DC: Department of Defense. 2002. http://www.gulflink.osd.mil/ khamisiyah-iii/(accessed 29 April 2010).
7. Woodall J. Tokyo subway gas attack. Lancet 1997;350:296.
8. O'Hern MR, Dashiell TR, Tracy MF. Chemical Defense Equipment. In: Sidell FR, Takafuji ET, Franz DR, eds. Medical Aspects of Chemical and Biological Warfare. In: Zajtchuk R, Bellamy R F, eds. Textbook of Military Medicine; Washington, DC: Department of the Army, Office of the Surgeon General, Borden Institute. 1997:361-396.
9. Hurst CG. Decontamination. In: Sidell FR, Takafuji ET, Franz DR, eds. Medical Aspects of Chemical and Biological Warfare. In: Zajtchuk R, Bellamy R F, eds. Textbook of Military Medicine; Washington, DC: Department of the Army, Office of the Surgeon General, Borden Institute. 1997:351-396.
10. Joint Requirements Office for Chemical, Biological, Radiological and Nuclear Defense. Joint Service Personnel/Skin Decontamination System (JSPDS) ; Washington, DC: Joint Requirements Office, Operational Requirements Document. 2004.
11. Bide RW, Burczyk AF, Risk DJ. Comparison of skin decontaminants for HD: Canadian Reactive Skin Decontaminant Lotion, Canadian Decontaminating Mitt and US Skin Decontaminating Kit. In: Proceedings of the 1996 Medical Defense Bioscience Review, Aberdeen Proving Ground, MD: U. S. Army Medical Research Institute of Chemical Defense. Vol No. III, AD A321842. 1996:1218-1227.
12. Bide RW, Risk DJ. Decontamination of GF in vivo by the Reactive Skin Decontamination Lotion (RSDL) ; Suffield, Canada: Defence R&D. 2002. Technical Memorandum, TM 2002-046.
13. Smart JK. History of chemical and biological warfare: an American perspective. In: Sidell FR, Takafuji ET, Franz DR, eds. Medical Aspects of Chemical and Biological Warfare. In: Zajtchuk R, Bellamy RF, eds. Textbook of Military Medicine; Washington, DC: Department of the Army, Office of the Surgeon General, Borden Institute. 1997:9-86.
14. Papirmeister B, Feister AJ, Robinson SI, Ford, RD. Medical Defense against Mustard Gas: Toxic Mechanisms and Pharmacological Implications; Boca Raton, FL: CRC Press. 1991:2.
15. Braue EH Jr, Doxzon BF, Lumpkin HL, Hanssen KA Graham JS. Military perspectives in chemical penetration retardation. In: Smith EW Maibach HI, eds. Percutaneous Penetration Enhancers-Volume 2; Boca Raton, FL: CRC Press. 2006:385-397.
16. Feder PI, Hobson DW, Olson CT, Joiner RL, Matthews MC. A. Stagewise, adaptive dose allocation for quantal response dose-response studies. Neurosci Behav Rev 1991;15:109-114.
17. Feder PI, Olson CT, Hobson DW, Matthews MC, Joiner RL. B. Stagewise, group sequential experimental designs for quantal responses. One-sample and two-sample comparisons. Neurosci Behav Rev 1991;15:129-133.
18. Finney DJ. Probit Analysis, 3rd ed; Cambridge, UK: Cambridge University Press. 1971.
19. Nelson WB. Applied Life Data Analysis; New York: John Wiley and Sons. 1982:374.
20. Maxwell DM, Koplovitz I, Worek F, Sweeney RE. A structure-activity analysis of the variation in oxime efficacy against nerve agents. Toxicol Appl Pharmacol 2008;231:157-164.
21. McDonough JH, Van Shura KE, LaMont JC, McMonagle JD, Shih TM. Comparison of the intramuscular, intranasal or sublingual routes of midazolam administration for the control of soman-induced seizures. Basic Clin Pharmacol Toxicol 2008;104:27-34.
22. Lenz DE, Maxwell DM, Koplovitz I, Clark CR, Capacio BR, Cerasoli DM,, et al. Protection against soman or VX poisoning by human butyrylcholinesterase in guinea pigs and cynomolgus monkeys. Chem Biol Interact 2005;157-158:205-210. (Pubitemid 41757652)
23. Gordon JJ, Leadbeater L, Maidment MP. The protection of animals against organophosphorus poisoning by pretreatment with a carbamate. Appl Pharmacol 1978;43:207-216. (Pubitemid 8274260)
24. Joiner RL, Harroff HH, Kiser RC, Feder, PI. Validation of a Protocol to Compare the Effectiveness of Experimental Decontaminants with the Single Most Effective Component of the M258A1 Kit or with Fuller's Earth Against Percutaneous Application of Undiluted Organophosphorus Chemical Surety Material to the Laboratory Albino Rabbit. Ft. Detrick, MD: U. S. Army Medical Research and Materiel Command. 1987. Battelle Memorial Institute Final Report on Task Order 84-2 (AD B115308).
25. Keo J. In vivo assessment of dermal absorption. In: Hobson DW, ed. Dermal and Ocular Toxicology Fundamentals and Methods, 1st ed; Ann Arbor, MI: CRC Press. 1991:267-296.
26. Koplovitz I, Stewart JR, Olson CT, Dill G, Menton R. Multispecies evaluation of the efficacy of HI6, a nerve agent antidote. In: Proceedings of the 1991 Medical Defense Bioscience Review; Aberdeen Proving Ground, MD: U. S. Army Medical Research Institute of Chemical Defense. AD B158588, 1991.
27. Ecobichon DJ, ed. The Basis of Toxicity Testing, 1st ed; Ann Arbor, MI: CRC Press. 1992.
28. Hall LL, Shal PV. In vivo methods for determining percutaneous absorption and metabolism of xenobiotics: indirect methods. In: Kemppainen BW, Reifenwrath WG, eds. Methods for Skin Absorption, 1st ed; Ann Arbor, MI: CRC Press. 1990:81-110.
29. Klain GJ, Reifenwrath WG. In vivo assessment of dermal absorption. In: Hobson DW, ed. Dermal and Ocular Toxicity Fundamentals and Methods, 1st ed; Ann Arbor, MI: CRC Press. 1991:247-266.
30. Decandole CA, Douglas WW, Evans CW, Holmes R, Spencer KEV, Torrance RW,, and Wilson KM. The failure of respiration in death by anticholinesterase poisoning. Br J Pharmacol 1953;8:466-475.
31. Trevor AJ, Miller RD. General anesthetics. In: Katzung BG, ed. Basic and Clinical Pharmacology, 5th ed; Norwalk, CT: Appleton and Lange. 1992:350-362.
32. Skvorak JP, Shutz MB, Shultz SM, Railer RF, Macalalag RC. Percutaneous toxicity of two novel organophosphorus compounds and the efficacy of currently fielded countermeasures. USAMRICD-TR-00-07. Aberdeen Proving Ground, MD: U. S. Army Medical Research Institute of Chemical Defense. 2000.
33. Clarkson ED, Logan TP, Lukey BJ, Maxwell D, Newkirk KT, Skvorak JB. Characterization of solvent effects on cutaneous exposure to chemical warfare agents GD and VX [abstract 205.17]. Society for Neuroscience Meeting Abstracts, 2002. http://www.sfn.org/index.cfm?pagename=abstracts-ampublications (accessed 29 April 2010).
34. Sidell FR, Newmark J, McDonough JH. Nerve agents. In: Tuorinsky SD, ed. Medical Aspects of Chemical Warfare. In: Lenhart, MK, ed. Textbook of Military Medicine; Washington, DC: Department of the Army, Office of the Surgeon General, Borden Institute. 2008:167.
35. Medical Management of Chemical Casualties Handbook, 3rd Ed; Aberdeen Proving Ground, MD: U. S. Army Medical Research Institute of Chemical Defense. 2000:175.
36. Hamilton MG, Hill I, Conley J, Sawyer TW, Caneva DC, Lundy PM. Clinical aspects of percutaneous poisoning by the chemical warfare agent VX: effects of application site and decontamination. Mil Med 2004;169:856-862. (Pubitemid 40797190)